No Data
Wuzhou Zhongheng to Transfer Stake in Lummy Pharma
Wuzhou Zhongheng Unit Gets Nod for Two Specifications for Alanyl Glutamine Injection
After consecutive years of losses, "abandoned"? Guangxi Wuzhou Zhongheng Group plans to transfer control of Chongqing Lummy Pharmaceutical | Quick Read Announcement.
①Guangxi Wuzhou Zhongheng Group plans to transfer the shares of Chongqing Lummy Pharmaceutical held directly by the company through public solicitation, which may lead to changes in the controlling shareholder and actual controller of the latter. ②The "story" of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019, and the following April it became the major shareholder of Chongqing Lummy Pharmaceutical, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous state of losses.
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary, the injection of N-acetylglycylglutamine, has obtained the supplementary application approval notice for pharmaceuticals.
Guangxi Wuzhou Zhongheng Group (600252.SH) announced on November 26 that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical") has received two specifications (10g in 50ml and 20g in 100ml) of Acetylcysteine Taurine Injection Supplementary Approval Notices issued by the National Medical Products Administration. Acetylcysteine Taurine Injection is a dipeptide nutritional solution developed by German Fresenius Kabi, marketed under the name Dipeptiven. This pharmaceutical, as part of the clinical nutrition program, is suitable for patients requiring taurine supplementation outside the intestines.
Guangxi Wuzhou Zhongheng Group (600252.SH): Intends to agree to transfer 23.43% of the shares of Chongqing Lummy Pharmaceutical.
On November 26, Gelonghui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced it plans to transfer its 247,426,064 freely transferable A-shares of Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical") through a public solicitation for transferees, accounting for 23.43% of Lummy Pharmaceutical's total share capital. If this public transfer of shares is completed, it may lead to changes in the controlling shareholder and actual controller of Lummy Pharmaceutical.
Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Adds CN¥981m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 14%
Lacklustre Performance Is Driving Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/SNo Data
No Data
